what happens when you stop glp-1 Really Taking Medications Weight loss maintenance after discontinuing

What is new

has received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Pharmaserve Lilly and Novo Nordisk, for advisory boards from Novo Nordisk, and has participated in sponsored studies by Eli-Lilly and Novo Nordisk

Prepregnancy BMI and the risk of gestational diabetes: a systematic review of the literature with meta-analysis

RCT SUMMIT - Tirzepatide vs Placebo for Heart Failure with Preserved Ejection Fraction and Obesity, NEJM (2024) [PubMed abstract] The SUMMIT trial enrolled 731 patients with heart failure, an ejection fraction of at least 50%, and a BMI of 30 or more Main inclusion criteria Age 40 years NYHA class II-IV EF 50% BMI 30 KCCQ-CSS of 80 or lower Main exclusion criteria Cardiomyopathy Uncontrolled hypertension History of bariatric surgery HbA1c 9.5% Baseline characteristics Age - 65.3 years Female sex - 53.8% NYHA class: II - 72.5% | III or IV - 27.5% Average body weight - 227 lbs (103 kg) Average BMI - 38.3 Average EF - 60.8% History of CAD - 30% Median NT-proBNP level - 183 pg/ml Average GFR - 64.4 ml/min Average KCCQ-CSS score - 53.6 Heart failure exacerbation within 12 months - 46.9% Atrial fibrillation - 25.5% Type 2 diabetes - 48.2% Randomized treatment groups Group 1 (364 patients): Tirzepatide with a target dose of 15 mg once weekly Group 2 (367 patients): Placebo Tirzepatide was started at 2.5 mg once weekly and increased by 2.5 mg every 4 weeks as tolerated (1) Composite of adjudicated death from cardiovascular causes or a worsening heart-failure event

Table 1 summarizes the RCTs that measured the weight-reducing effects and the other secondary outcomes of GLP-1RA in PCOS patients

Moreover, these insulin-sensitizing effects of tirzepatide could be replicated with chronic GIPR agonism alone